Drug or treatment

Epcoritamab clinical trials

• 31Clinical trials
• 1New in 30 days
• 19Countries

Newest trials

All recruiting trials (31)

• Pirtobrutinib and Epcoritamab vs R-(Mini)-CHOP for DLBCL-type Richter Transformation in older or frail adults

  This trial tests a fixed-duration treatment with Pirtobrutinib and Epcoritamab against a mini-CHOP regimen in adults age 80+ or who are frail with Richter transformation.

  Recruiting at 7 sites Phase 2 German CLL Study Group · Melbourne and 11 other locations · NCT07917780

• Low-dose epcoritamab with GemOx for relapsed/refractory DLBCL

  This trial will test whether adding a low dose of epcoritamab to GemOx chemotherapy helps people with relapsed or refractory diffuse large B‑cell lymphoma who are eligible for autologous stem cell transplant.

  Recruiting Phase 2 Hospital Universitario Dr. Jose E. Gonzalez · Monterrey, Nuevo León · NCT07451652

• Epcoritamab plus R-GemOx before autologous stem cell transplant for relapsed or refractory DLBCL

  This phase II trial tests whether adding epcoritamab to rituximab with gemcitabine and oxaliplatin (R-GemOx) can help adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) achieve remission and proceed to autologous stem cell transplant.

  Recruiting Phase 2 City of Hope Medical Center · Duarte, California and 2 other locations · NCT07365306

• NK cell therapy with epcoritamab and tafasitamab for relapsed or treatment‑resistant B‑cell lymphoma

  This trial will try whether adding donor-derived ONC-PluReceptor NK cells to the antibodies epcoritamab and tafasitamab helps control relapsed or refractory CD19/CD20-positive B‑cell non‑Hodgkin lymphoma.

  Recruiting Phase 1/2 M.D. Anderson Cancer Center · Houston, Texas · NCT07283679

• Venetoclax plus obinutuzumab followed by epcoritamab for untreated CLL/SLL

  This trial tests whether giving venetoclax and obinutuzumab followed by epcoritamab can produce deep remissions in people with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.

  Recruiting at 4 sites Phase 2 City of Hope Medical Center · Duarte, California and 6 other locations · NCT07218510

• Combining loncastuximab tesirine and epcoritamab in relapsed/refractory aggressive B‑cell lymphoma

  In this phase 2 study, researchers will test whether the drug combo loncastuximab tesirine plus epcoritamab can help people with relapsed or refractory aggressive B‑cell lymphomas, including DLBCL, HGBL, or FL 3B, who have failed prior therapies or CAR‑T treatment.

  Recruiting at 30 sites Phase 2 Universität Münster · Aachen and 33 other locations · NCT07197307

• Epcoritamab with response-adaptive escalation for first-relapse large B‑cell lymphoma

  This will try epcoritamab alone for three cycles and, for some patients, switch to epcoritamab plus tafasitamab and lenalidomide to see if it improves response in people with first-relapse large B‑cell lymphoma.

  Recruiting at 19 sites Phase 2 Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea · Seville, Andalusia and 18 other locations · NCT07126236

• Epcoritamab given after 2nd-generation BTK inhibitors for CLL/SLL

  This trial will try giving subcutaneous epcoritamab for up to 12 cycles to adults with CLL/SLL who have been on a second‑generation BTK inhibitor for at least 12 months to see if it can deepen responses to a complete remission with undetectable MRD so therapy can be stopped.

  Recruiting Phase 2 University of Cincinnati · Cincinnati, Ohio · NCT07108998

• Epcoritamab plus dose‑adjusted EPOCH‑R for aggressive B‑cell lymphoma

  This trial tests whether adding epcoritamab to dose‑adjusted EPOCH‑R chemotherapy can safely improve outcomes for adults with untreated aggressive B‑cell non‑Hodgkin lymphoma.

  Recruiting Phase 2 University of Washington · Seattle, Washington · NCT07097363

• Epcoritamab plus ibrutinib for central nervous system lymphoma

  This trial tests whether combining epcoritamab and ibrutinib is safe and tolerable for adults with relapsed or refractory primary or secondary central nervous system lymphoma.

  Recruiting at 8 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 7 other locations · NCT07082868

• Epcoritamab with lenalidomide and rituximab for relapsed or refractory primary diffuse large B‑cell lymphoma of the CNS

  This phase 2 test tries to see if adding epcoritamab to lenalidomide and rituximab helps adults with relapsed or refractory primary CNS diffuse large B‑cell lymphoma.

  Recruiting at 9 sites Phase 2 The Lymphoma Academic Research Organisation · Bordeaux and 12 other locations · NCT06931652

• Epcoritamab plus loncastuximab tesirine for relapsed or refractory large B-cell lymphoma

  This test gives epcoritamab together with loncastuximab tesirine to adults whose large B-cell lymphoma has come back or not responded, to see if it can shrink or clear the cancer.

  Recruiting Phase 2 University of Miami · Miami, Florida · NCT06919939

• Epcoritamab with platinum chemotherapy and autologous stem cell transplant for relapsed or refractory large B-cell lymphoma

  This trial tests whether adding epcoritamab to standard platinum-based salvage chemotherapy followed by an autologous stem cell transplant helps adults with relapsed or refractory large B-cell lymphoma.

  Recruiting Phase 2 University of California, Davis · Sacramento, California · NCT06905509

• Assessing Epcoritamab for Adult Patients with Advanced Lymphoma

  This study is testing if a new skin injection called epcoritamab can help adults with advanced lymphoma feel better and improve their health.

  Recruiting at 73 sites AbbVie · Ciudad Autonoma de Buenos Aire, Buenos Aires and 72 other locations · NCT06830759

• Outpatient epcoritamab for second-line, non-transplant-eligible relapsed/refractory diffuse large B‑cell lymphoma

  This tests whether outpatient epcoritamab can help adults with relapsed or refractory large B‑cell lymphoma who are not eligible for transplant after one prior therapy.

  Recruiting at 2 sites Phase 2 Massachusetts General Hospital · Boston, Massachusetts and 1 other locations · NCT06811272

• Epcoritamab for newly diagnosed marginal zone lymphoma

  This trial will test whether the antibody drug epcoritamab helps adults who are newly diagnosed with marginal zone lymphoma.

  Recruiting Phase 2 University of Miami · Miami, Florida · NCT06796998

• Epcoritamab and Lenalidomide for Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma

  This phase 2 trial checks if the combination of epcoritamab and lenalidomide can help people with immune-related large B-cell lymphoma that hasn’t responded to treatment or has come back.

  Recruiting Phase 2 Northwestern University · Chicago, Illinois · NCT06723457

• Epcoritamab treatment for relapsed or refractory post-transplant lymphoproliferative disorders

  This study is testing a new treatment called epcoritamab to see if it can help people with relapsed or stubborn post-transplant lymphoproliferative disorders feel better.

  Recruiting at 2 sites Phase 1 Ohio State University Comprehensive Cancer Center · St Louis, Missouri and 1 other locations · NCT06672705

• Combination treatment for relapsed or refractory follicular lymphoma

  This study is testing a new combination of three medications to see if it can help people with relapsed or refractory follicular lymphoma feel better.

  Recruiting at 3 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 2 other locations · NCT06563596

• Combination treatment of epcoritamab and ibrutinib for aggressive B-cell lymphoma

  This study is testing a new combination of two treatments, epcoritamab and ibrutinib, to see if they can help people with aggressive B-cell lymphoma that hasn't responded to other therapies.

  Recruiting at 3 sites Phase 1/2 Ohio State University Comprehensive Cancer Center · Minneapolis, Minnesota and 2 other locations · NCT06536049

• Using epcoritamab to treat previously treated Waldenstrom Macroglobulinemia

  This study is testing if a new treatment called epcoritamab can help people with Waldenstrom Macroglobulinemia who have already received other treatments.

  Recruiting at 3 sites Phase 2 Beth Israel Deaconess Medical Center · Boston, Massachusetts and 2 other locations · NCT06510491

• Epcoritamab treatment for patients with follicular lymphoma not responding to initial therapy

  This study is testing if a new treatment called epcoritamab can help people with follicular lymphoma who didn't respond well to their first therapy.

  Recruiting at 3 sites Phase 2 Beth Israel Deaconess Medical Center · Stanford, California and 2 other locations · NCT06510361

• Epcoritamab treatment for certain types of lymphoma

  This study is testing if adding a new treatment called epcoritamab to CAR T cell therapy can help people with certain types of lymphoma who haven't fully responded to previous treatments.

  Recruiting Phase 2 Abramson Cancer Center at Penn Medicine · Philadelphia, Pennsylvania · NCT06458439

• Preventing cytokine release syndrome with siltuximab before epcoritamab treatment

  This study is testing if giving siltuximab before treatment with epcoritamab can help prevent serious side effects in people with large B-cell lymphoma or follicular lymphoma.

  Recruiting Phase 1 Case Comprehensive Cancer Center · Cleveland, Ohio · NCT06447376

• Epcoritamab treatment for patients with large B-cell lymphoma after CAR T-cell therapy

  This study is testing if a new treatment called Epcoritamab, either on its own or with two other drugs, can help patients with large B-cell lymphoma who haven't responded well after CAR T-cell therapy.

  Recruiting at 3 sites Phase 2 Peter MacCallum Cancer Centre, Australia · Camperdown, New South Wales and 5 other locations · NCT06414148

• Combination therapy with Epcoritamab for relapsed aggressive B-cell lymphoma

  This study is testing if adding Epcoritamab to chemotherapy helps people with relapsed aggressive B-cell lymphoma get better before a stem cell transplant and live longer without the disease coming back.

  Recruiting Phase 2 Australasian Leukaemia and Lymphoma Group · Melbourne, Victoria · NCT06287398

• Epcoritamab for B-cell lymphoma patients not fully responding to CAR-T therapy

  This study is testing if a new treatment called epcoritamab can help people with B-cell lymphoma who didn't fully respond to CAR-T therapy feel better and improve their chances of survival.

  Recruiting Phase 2 Academic and Community Cancer Research United · Rochester, Minnesota and 5 other locations · NCT06238648

• Combining Epcoritamab with Rituximab-mini CVP for Older Patients with Newly Diagnosed Large B-cell Lymphoma

  This study is testing if adding a new drug called epcoritamab to the standard treatment for older patients with newly diagnosed large B-cell lymphoma can improve their chances of recovery.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT06045247

• Combination therapy for relapsed large cell lymphoma using epcoritamab and chemotherapy

  This study is testing a new combination of treatments for people with relapsed large cell lymphoma to see if it helps them respond better after previous therapies.

  Recruiting at 4 sites Phase 2 Hoosier Cancer Research Network · Indianapolis, Indiana and 3 other locations · NCT05852717

• Combining venetoclax with epcoritamab for treating relapsed or refractory CLL or SLL

  This study is testing a new combination of two treatments, venetoclax and epcoritamab, to see if they can help people with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) feel better.

  Recruiting at 25 sites Phase 1/2 Stichting Hemato-Oncologie voor Volwassenen Nederland · Melbourne and 28 other locations · NCT05791409

• Epcoritamab plus rituximab as first treatment for follicular lymphoma

  This trial tests whether adding epcoritamab to rituximab is safe and effective as the first treatment for adults with untreated follicular lymphoma.

  Recruiting at 6 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 5 other locations · NCT05783609

Quick answers

How many clinical trials of Epcoritamab are recruiting right now?

31, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 19 countries. The most sites are in United States (22 trials), Australia (5 trials), Germany (3 trials), Spain (2 trials), Austria (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 24, Phase 1: 3, Phase 1/2: 3. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →